Shares of Cryolife Inc (NYSE:CRY) have earned an average rating of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $25.83.
Several brokerages have recently commented on CRY. Canaccord Genuity restated a “buy” rating and set a $28.00 target price (up previously from $25.00) on shares of Cryolife in a report on Friday, March 9th. Northland Securities restated a “buy” rating and set a $23.50 target price on shares of Cryolife in a report on Thursday, March 8th. Zacks Investment Research upgraded Cryolife from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, ValuEngine cut Cryolife from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th.
In related news, Director C Elkins Ronald sold 2,000 shares of the firm’s stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $22.00, for a total value of $44,000.00. Following the transaction, the director now owns 97,849 shares in the company, valued at $2,152,678. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.00% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of CRY. Teacher Retirement System of Texas bought a new position in Cryolife in the fourth quarter valued at about $197,000. Metropolitan Life Insurance Co. NY bought a new position in Cryolife in the fourth quarter valued at about $203,000. Crossmark Global Holdings Inc. bought a new position in Cryolife in the third quarter valued at about $259,000. Stifel Financial Corp bought a new position in Cryolife in the third quarter valued at about $275,000. Finally, Hartford Investment Management Co. bought a new position in Cryolife in the third quarter valued at about $276,000. Institutional investors and hedge funds own 73.99% of the company’s stock.
Shares of Cryolife (CRY) traded up $0.10 during mid-day trading on Friday, hitting $20.85. The stock had a trading volume of 87,278 shares, compared to its average volume of 109,670. The company has a quick ratio of 4.90, a current ratio of 4.18 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $753.53, a PE ratio of 208.50 and a beta of 0.75. Cryolife has a 12 month low of $14.02 and a 12 month high of $24.00.
Cryolife (NYSE:CRY) last announced its earnings results on Wednesday, March 7th. The medical equipment provider reported $0.11 EPS for the quarter, hitting the consensus estimate of $0.11. The company had revenue of $52.80 million for the quarter, compared to analysts’ expectations of $48.40 million. Cryolife had a return on equity of 5.93% and a net margin of 1.95%. The business’s revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.09 earnings per share. equities research analysts forecast that Cryolife will post 0.09 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/cryolife-inc-cry-receives-consensus-recommendation-of-hold-from-analysts.html.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.